Mallinckrodt Plc (Mallinckrodt) develops, produces, markets, and distributes specialty pharmaceutical products and therapies. The company offers branded pharmaceutical products for autoimmune and rare diseases in specialty areas such as rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers immunotherapy, oncology and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company offers specialty generic drugs and active pharmaceutical ingredients. Mallinckrodt markets branded products directly to physicians, specialty pharmacies, hospitals and ambulatory surgical centers; and also distributes branded and generic products through a network of drug distributors, specialty pharmaceutical distributors and retail pharmacy chains, among others. It has facilities in the US, Ireland, Japan and other countries. Mallinckrodt is headquartered in Dublin, Ireland.

Headquarters Ireland

Address College Business & Technology Park, Cruiserath, Blanchardstown, Dublin


Telephone 353 1 8207940

No of Employees 2,800

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange MNKKQ (OTC)

Revenue (2021) $2.2B -19.7% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 24.1% (2021 vs 2020)

Market Cap* $710,000

Net Profit Margin (2021) XXX 5.5% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

310+

Clinical Trials

Determine Mallinckrodt Plc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

60+

Marketed Drugs

Understand Mallinckrodt Plc’s commercialized product portfolio to stay one step ahead of the market.

40+

Pipeline Drugs

Identify which of Mallinckrodt Plc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

20+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

20+

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

20+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Mallinckrodt Plc’s relevant decision makers and contact details.

20+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

17+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Mallinckrodt Plc and assess market opportunity for new entrants with patient population 8-year forecasts.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Specialty Brands:
Repository Corticotropin Injection
Nitricoxide
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 New Product Approvals In June, the company received U.S. FDA Approval of StrataGraft
2021 New Product Approvals In March, the company received U.S. FDA Approval of Updated Acthar Gel
2021 New Product Approvals In January, the company received approval from Japan's Ministry of Health, Labour and Welfare for Cwellex for the treatment of Graft versus host disease.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Mallinckrodt Plc Bayer AG Merck & Co Inc Eli Lilly and Co Johnson Matthey Plc
Headquarters Ireland Germany United States of America United States of America United Kingdom
City Dublin Leverkusen Whitehouse Station Indianapolis London
State/Province - Nordrhein-Westfalen New Jersey Indiana -
No. of Employees 2,800 100,753 68,000 35,000 14,421
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Mark Trudeau Chief Executive Officer; President; Director Executive Board 2013 60
Bryan M. Reasons Executive Vice President; Chief Financial Officer Senior Management 2019 53
Mark J. Casey Chief Legal Officer; Executive Vice President Senior Management 2019 58
Brandi Robinson Senior Vice President; Chief Communications Officer Senior Management - -
Tunde Otulana, M.D. Chief Medical Officer; Senior Vice President Senior Management 2016 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer